148 related articles for article (PubMed ID: 8916958)
1. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
[TBL] [Abstract][Full Text] [Related]
2. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
4. The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Lishner M; Slingerland J; Theresa C; Sutcliffe SB
Leuk Lymphoma; 1994 Mar; 13(1-2):131-6. PubMed ID: 7517744
[TBL] [Abstract][Full Text] [Related]
5. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prognosis of orbital non-Hodgkin's lymphomas.
Platanias LC; Putterman AM; Vijayakumar S; Recant W; Weichselbaum RR; Bitran JD
Am J Clin Oncol; 1992 Feb; 15(1):79-83. PubMed ID: 1372464
[TBL] [Abstract][Full Text] [Related]
7. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
Armitage JO
Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
[TBL] [Abstract][Full Text] [Related]
8. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS
Blood; 1995 Apr; 85(7):1727-35. PubMed ID: 7535586
[TBL] [Abstract][Full Text] [Related]
9. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ
Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651
[TBL] [Abstract][Full Text] [Related]
10. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
11. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Waits TM; Greco FA; Greer JP; Hainsworth JD
Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
[TBL] [Abstract][Full Text] [Related]
12. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Cassi E; Butti C; Baldini L; Pisoni GB; Ceriani A; Confalonieri C; Scandolaro L; De Paoli A; Lombardi F; Montalbetti L
Leuk Lymphoma; 1994 Mar; 13(1-2):111-8. PubMed ID: 7517742
[TBL] [Abstract][Full Text] [Related]
13. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE; Hoskins P; Klimo P; Connors JM
Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
[TBL] [Abstract][Full Text] [Related]
14. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
15. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
[TBL] [Abstract][Full Text] [Related]
17. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
18. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
[TBL] [Abstract][Full Text] [Related]
19. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Engelhard M; Brittinger G; Huhn D; Gerhartz HH; Meusers P; Siegert W; Thiel E; Wilmanns W; Aydemir U; Bierwolf S; Griesser H; Tiemann M; Lennert K
Blood; 1997 Apr; 89(7):2291-7. PubMed ID: 9116271
[TBL] [Abstract][Full Text] [Related]
20. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
